title: Antiviral combination therapy with interferon/peginterferon plus ribavirin for patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Agency for Health Technology Assessment.
abstract: OBJECTIVE
  The purpose of this health technology assessment (HTA), commissioned by the German Agency for HTA at the German Federal Ministry of Health and Social Security, was to systematically review the evidence on effectiveness and cost-effectiveness of antiviral treatment (AVT) for initial chronic hepatitis C (CHC) and to apply these data in the context of the German health care system.
  
  
  METHODS
  A systematic literature search was conducted to identify randomised controlled trials (RCTs), meta-analyses, and HTAs that evaluated initial AVT for CHC. A modified version of the German Hepatitis C Model (GEHMO)--a decision-analytic Markov model--was used to determine long-term morbidity, life expectancy, quality of life, costs and cost-effectiveness of different treatment strategies. Model parameters were derived from German databases, international RCTs, and a Cochrane Review.
  
  
  RESULTS
  Overall, 9 RCTs, 2 HTA reports, 1 Cochrane review, and 2 meta-analyses examining medical effectiveness of antiviral combination therapy, as well as 7 economic evaluations, met the inclusion criteria. These studies indicate that combination therapy with peginterferon plus ribavirin produced the highest sustained virological response rates (54-61%), followed by interferon plus ribavirin with 38-54%, and interferon monotherapy with 11-21%. Based on international cost-effectiveness studies, interferon plus ribavirin is cost-effective compared to interferon monotherapy. No published articles were available regarding cost-effectiveness of peginterferon plus ribavirin. In our decision analysis, these findings were confirmed and the discounted incremental cost-effectiveness ratio for peginterferon plus ribavirin was euro 9,800 per quality-adjusted life-year gained compared to interferon monotherapy (as the next best non-dominated strategy). Sensitivity analyses showed robust results across a wide range of model parameters.
  
  
  CONCLUSIONS
  This HTA suggests that initial combination therapy prolongs life, improves quality of life, and is cost-effective in patients with CHC. Combination of peginterferon and ribavirin is the most effective and efficient treatment strategy among the examined options.
authors.affiliation: Program on Health Technology Assessment and Decision Sciences, Bavarian Public Health Research and Coordinating Center, Institute of Medical Informatics, Biometry, and Epidemiology, Ludwig-Maximilians-University Munich, Germany. siebert@ibe.med.uni-muenchen.de
authors.forename: Uwe
authors.initials: U
authors.lastname: Siebert
authors.forename: Gaby
authors.initials: G
authors.lastname: Sroczynski
references.citation: Ann Intern Med. 2000 Feb 15;132(4):296-305
references.pmid: 10681285
references.citation: Liver. 1993 Oct;13(5):274-8
references.pmid: 7505044
references.citation: J Hepatol. 2000 Oct;33(4):651-8
references.pmid: 11059872
references.citation: J Hepatol. 2001 Mar;34(3):441-6
references.pmid: 11322207
references.citation: Health Technol Assess. 2000;4(33):1-67
references.pmid: 11134916
references.citation: Hepatology. 2002 Nov;36(5 Suppl 1):S47-56
references.pmid: 12407576
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: J Hepatol. 1990 Jan;10(1):69-76
references.pmid: 2106548
references.citation: Semin Liver Dis. 1999;19 Suppl 1:57-65
references.pmid: 10349693
references.citation: Hepatology. 2001 Oct;34(4 Pt 1):809-16
references.pmid: 11584380
references.citation: N Engl J Med. 1999 Aug 19;341(8):556-62
references.pmid: 10451460
references.citation: Hepatology. 1999 Nov;30(5):1318-24
references.pmid: 10534357
references.citation: Ann Intern Med. 1990 Dec 1;113(11):852-71
references.pmid: 2146912
references.citation: Health Policy. 1996 Sep;37(3):163-83
references.pmid: 10160021
references.citation: Gastroenterology. 1996 Nov;111(5):1307-12
references.pmid: 8898645
references.citation: Gut. 2002 Feb;50(2):253-8
references.pmid: 11788569
references.citation: J Hepatol. 1999 May;30(5):956-61
references.pmid: 10365827
references.citation: Lancet. 1998 Jan 10;351(9096):83-7
references.pmid: 9439491
references.citation: Health Econ. 1998 Sep;7(6):481-93
references.pmid: 9809707
references.citation: Am J Gastroenterol. 2000 Jun;95(6):1524-30
references.pmid: 10894590
references.citation: BMJ. 2001 Nov 17;323(7322):1151-5
references.pmid: 11711405
references.citation: Cochrane Database Syst Rev. 2002;(1):CD002234
references.pmid: 11869633
references.citation: Pharmacoeconomics. 1998;14 Suppl 2:39-56
references.pmid: 10344922
references.citation: Hepatology. 1991 Dec;14(6):969-74
references.pmid: 1959884
references.citation: J Hepatol. 1992 Nov;16(3):273-81
references.pmid: 1487603
references.citation: Eur J Gastroenterol Hepatol. 2001 May;13(5):483-8
references.pmid: 11396525
references.citation: Ann Intern Med. 1999 May 18;130(10):857-8
references.pmid: 10366377
references.citation: Am J Med. 2000 Apr 1;108(5):366-73
references.pmid: 10759092
references.citation: J Viral Hepat. 1999 Jan;6(1):35-47
references.pmid: 10847128
references.citation: N Engl J Med. 1998 Nov 19;339(21):1485-92
references.pmid: 9819446
references.citation: Ann Intern Med. 1993 Jul 15;119(2):110-5
references.pmid: 8512159
references.citation: J Hepatol. 2000 Sep;33(3):448-55
references.pmid: 11020001
references.citation: Lancet. 1998 Oct 31;352(9138):1426-32
references.pmid: 9807989
references.citation: Int J Technol Assess Health Care. 1992 Fall;8(4):671-82
references.pmid: 1464487
references.citation: Scand J Gastroenterol. 2001 Aug;36(8):870-6
references.pmid: 11495084
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Semin Liver Dis. 2000;20(1):17-35
references.pmid: 10895429
references.citation: Ann Intern Med. 1997 Nov 15;127(10):855-65
references.pmid: 9382363
references.citation: J Hepatol. 1995;23 Suppl 2:8-12
references.pmid: 8720287
references.citation: Hepatology. 1994 Jun;19(6):1513-20
references.pmid: 8188183
references.citation: Hepatology. 1981 Sep-Oct;1(5):431-5
references.pmid: 7308988
references.citation: J Gastroenterol Hepatol. 2002 Apr;17(4):423-30
references.pmid: 11982723